We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -6.06% | 1.55 | 1.50 | 1.60 | 1.65 | 1.475 | 1.65 | 8,522,072 | 16:15:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.30 | 12.02M |
From May 2019 to May 2024
TIDMSTX TIDMSTXW
RNS Number : 2980G
Shield Therapeutics PLC
26 May 2017
Shield Therapeutics plc
("Shield" or the "Group")
Appointment of Joint Broker
London, UK, 26 May 2017: Shield Therapeutics plc (LSE:STX), a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, today announces that it has appointed Peel Hunt LLP to act as its Joint Broker with immediate effect to act alongside Liberum Capital Limited, who will continue to act as Nominated Adviser and Joint Broker to Shield.
-Ends-
For further information please contact:
Hot Features
Premium
+44 (0) 20 7467
Shield Therapeutics plc 6920
Carl Sterritt, Chief Executive
Officer
Joanne Estell, Chief Financial
Officer
Nominated Adviser and Joint +44 (0)20 3100
Broker 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
+ 44 (0)20 7418
Joint Broker 8900
Peel Hunt LLP
James Steel/Dr. Christopher
Golden
+44 (0)203 709
Financial PR Advisor 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDBGDULSDBGRU
(END) Dow Jones Newswires
May 26, 2017 02:01 ET (06:01 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
